Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLP005
MIFTS: 44

Blepharitis

Categories: Eye diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Blepharitis

About this section

MalaCards integrated aliases for Blepharitis:

Name: Blepharitis 12 77 38 56 6 45 15 17 74

Classifications:

MalaCards categories:
Anatomical: Eye diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:9423
KEGG 38 H01644
MeSH 45 D001762
NCIt 51 C112183
SNOMED-CT 69 41446000
Sources

Summaries for Blepharitis

About this section
Disease Ontology : 12 An eyelid disease that is characterized by often chronic inflammation of the eyelid, generally the part where eyelashes grow.

MalaCards based summary : Blepharitis is related to blepharoconjunctivitis and keratoconjunctivitis, and has symptoms including erythema of the eyelids An important gene associated with Blepharitis is STAT1 (Signal Transducer And Activator Of Transcription 1), and among its related pathways/superpathways are Immune response Role of DAP12 receptors in NK cells and Development IGF-1 receptor signaling. The drugs Acitretin and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and testes, and related phenotypes are hematopoietic system and immune system

Wikipedia : 77 Blepharitis (/blɛfəˈraɪtɪs/ BLEF-ər-EYE-tis) is one of the most common ocular conditions characterized... more...

Sources

Related Diseases for Blepharitis

About this section

Diseases related to Blepharitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Related Disease Score Top Affiliating Genes
1 blepharoconjunctivitis 31.7 CCL11 CMA1 IL4 SHE
2 keratoconjunctivitis 29.9 CCL11 IL4
3 dermatitis 29.9 CCL11 CMA1 IL4
4 papillary conjunctivitis 29.9 CCL11 IL4
5 giant papillary conjunctivitis 29.9 CCL11 IL4
6 dermatitis, atopic 29.5 CCL11 CMA1 IL4
7 ulcerative blepharitis 12.3
8 squamous blepharitis 12.3
9 meibomian cyst 11.4
10 focal facial dermal dysplasia 3, setleis type 11.2
11 keratosis follicularis spinulosa decalvans, x-linked 11.2
12 ichthyosis, congenital, autosomal recessive 11 11.1
13 hordeolum externum 11.1
14 eyelid disease 11.1
15 conjunctivitis 10.5
16 herpes simplex 10.3
17 lupus erythematosus 10.3
18 rosacea 10.3
19 dermatophytosis 10.3
20 chronic meningitis 10.3 CCL11 MMP9
21 discoid lupus erythematosus 10.2
22 central nervous system tuberculosis 10.2 MMP9 STAT1
23 strongyloidiasis 10.2 CCL11 SHE
24 scleritis 10.1 IL4 MMP9
25 chromoblastomycosis 10.1 IL4 MMP9
26 eosinophilic gastritis 10.0 CCL11 IL4
27 kimura disease 10.0 CCL11 IL4
28 folliculitis 10.0 CCL11 IL4
29 keratitis, hereditary 10.0
30 crohn's colitis 10.0
31 phlyctenulosis 10.0
32 ectropion 10.0
33 conjunctival disease 10.0 CCL11 IL4
34 pulmonary eosinophilia 10.0 CCL11 IL4
35 onchocerciasis 10.0 CCL11 IL4
36 allergic conjunctivitis 10.0 CCL11 IL4
37 nasal cavity disease 9.9 CCL11 IL4
38 opportunistic mycosis 9.9 IL4 STAT1
39 angiostrongyliasis 9.9 CCL11 IL4 MMP9
40 eosinophilic meningitis 9.9 CCL11 IL4 MMP9
41 vernal keratoconjunctivitis 9.9 CCL11 IL4 MMP9
42 vernal conjunctivitis 9.9 CMA1 IL4
43 proteasome-associated autoinflammatory syndrome 1 9.9 CCL11 IL4 MMP9
44 respiratory system disease 9.9 CCL11 IL4 MMP9
45 autoimmune disease 9.9
46 systemic lupus erythematosus 9.9
47 melkersson-rosenthal syndrome 9.9
48 rheumatoid arthritis 9.9
49 trichomegaly 9.9
50 lipoid proteinosis of urbach and wiethe 9.9

Comorbidity relations with Blepharitis via Phenotypic Disease Network (PDN):


Acute Cystitis Conjunctivitis
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Hypertension, Essential
Parkinson Disease, Late-Onset Schizophreniform Disorder

Graphical network of the top 20 diseases related to Blepharitis:



Diseases related to Blepharitis
Sources

Symptoms & Phenotypes for Blepharitis

About this section

UMLS symptoms related to Blepharitis:


erythema of the eyelids

MGI Mouse Phenotypes related to Blepharitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 CCL11 CMA1 IL4 MMP9 PLA2G6 STAT1
2 immune system MP:0005387 9.56 CCL11 CMA1 IL4 MMP9 NIPBL PLA2G6
3 skeleton MP:0005390 9.1 IL4 MMP9 NIPBL PLA2G6 STAT1 WIPF1
Sources

Drugs & Therapeutics for Blepharitis

About this section

Drugs for Blepharitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acitretin Approved Phase 4 55079-83-9, 69427-46-9 6437841
2
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
3
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 441411 12560
4
Besifloxacin Approved Phase 4 141388-76-3
5
Azithromycin Approved Phase 4,Phase 3,Phase 2,Not Applicable 83905-01-5 447043 55185
6
Loteprednol Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 82034-46-6, 129260-79-3 9865442 444025
7
Tobramycin Approved, Investigational Phase 4,Phase 3,Not Applicable 32986-56-4 36294 5496
8
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
9
Minocycline Approved, Investigational Phase 4,Not Applicable 10118-90-8 5281021
10
Glycerol Approved, Investigational Phase 4 56-81-5 753
11
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
12
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
13
Dipivefrin Approved Phase 4,Phase 3 52365-63-6 3105
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 1177-87-3
15
Chloramphenicol Approved, Vet_approved Phase 4 56-75-7 5959 298
16
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
17
Fusidic Acid Approved, Investigational Phase 4 6990-06-3 3000226
18
Permethrin Approved, Investigational Phase 4 52645-53-1 40326
19
Chloramphenicol succinate Approved Phase 4 3544-94-3
20 Keratolytic Agents Phase 4
21 Dermatologic Agents Phase 4,Phase 2,Not Applicable
22 Ophthalmic Solutions Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
23 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
24 Viscosupplements Phase 4,Not Applicable
25 Immunologic Factors Phase 4,Phase 2,Not Applicable
26 Adjuvants, Immunologic Phase 4,Not Applicable
27 Protective Agents Phase 4,Not Applicable
28 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
29 Erythromycin stearate Phase 4
30 Erythromycin Ethylsuccinate Phase 4
31 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Not Applicable
32 Erythromycin Estolate Phase 4
33 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
34 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
35 Antibiotics, Antitubercular Phase 4,Phase 3,Not Applicable
36 Lubricant Eye Drops Phase 4,Phase 1,Phase 2
37 Antimalarials Phase 4,Phase 2,Not Applicable
38 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Not Applicable
39 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Not Applicable
40 Laxatives Phase 4
41 Carboxymethylcellulose Sodium Phase 4
42 Cathartics Phase 4
43 Analgesics, Non-Narcotic Phase 4
44 Analgesics Phase 4
45 Antirheumatic Agents Phase 4,Phase 1,Phase 2,Not Applicable
46 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
47 Anti-Inflammatory Agents, Non-Steroidal Phase 4
48 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
49 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
50 Tobramycin, Dexamethasone Drug Combination Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 72)
# Name Status NCT ID Phase Drugs
1 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
2 Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis Completed NCT01478256 Phase 4 Erythromycin;Besifloxocin
3 Efficacy and Safety of Posiformin 2 % Eye Ointment in the Treatment of Blepharitis Completed NCT01357538 Phase 4 Posiformin 2 %, bibrocathol;Placebo Comparator
4 Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis Completed NCT00629941 Phase 4 AzaSite®
5 Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis Completed NCT00656539 Phase 4 AzaSite®
6 Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis Completed NCT00629980 Phase 4 AzaSite®
7 Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis Completed NCT00629590 Phase 4 AzaSite®
8 Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis Completed NCT01456780 Phase 4 Loteprednol/tobramycin;Loteprednol;B+L Advanced Eye Relief Lubricant Drop
9 Lipids of the Human Tear Film and Their Effect on Tear Stability Completed NCT00803452 Phase 4 doxycycline;azithromycin
10 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
11 Topical Nepafenac as Supplement for Diabetic Macular Edema Completed NCT02443012 Phase 4 Topical Gutt Nepafenac 0.1%
12 Zylet vs TobraDex in Blepharokeratoconjunctivitis Completed NCT00447577 Phase 4 Loteprednol etabonate and tobramycin ophthalmic suspension;Tobramycin and dexamethasone ophthalmic suspension
13 The Efficacy of Permethrin 5%, Fusidic Acid 1% and Synthomycine 5% for Demodex - Blepharitis Enrolling by invitation NCT03105505 Phase 4 Permethrin 5%;Synthomycine 5%;Fusidic Acid 1% M/R Eye Drops
14 Manuka Eye Droops for Treatment of Allergy Not yet recruiting NCT03862053 Phase 4 Manuka honey
15 A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis Completed NCT01102244 Phase 3 Tobradex ST;Azasite
16 Treatment of Demodex Blepharitis With Ivermectin Gel 0.1% Plus Metronidazole 1% Completed NCT02236403 Phase 3 Ivermectin 0.1% Metronidazole 1%
17 Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis Completed NCT01408082 Phase 3 ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined);Azasite;Dexamethasone
18 Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis Completed NCT00732446 Phase 3 Moxifloxacin and Dexamethasone combined;Moxifloxacin;Dexamethasone
19 Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes Completed NCT00796926 Phase 3 Systane Ultra eyedrops;Refresh eye drops
20 Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis Completed NCT01028027 Phase 3 Loteprednol and tobramycin;Tobramycin and dexamethasone
21 Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops Completed NCT01087671 Phase 3 tafluprost
22 Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects Recruiting NCT01543490 Phase 3 ISV-305
23 Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection Withdrawn NCT01721694 Phase 3 azithromycin 1.5%/Loteprednol 0,5% + placebo;azithromycin 1.5% + Loteprednol 0,5% (separately)
24 Effects of Magnetic Therapy and Seawater Combined in Decreasing Intraocular Presion. Unknown status NCT02300818 Phase 1, Phase 2 Seawater eyedrops
25 Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101 Unknown status NCT02656394 Phase 2 GL101;Placebo
26 Oral Azithromycin Versus Doxycycline in Posterior Blepharitis Completed NCT01783860 Phase 2 Azithromycin;Doxycycline
27 Tea Tree Oil in the Treatment of Chronic Blepharitis Completed NCT01073150 Phase 2 Tea Tree Oil
28 Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis Completed NCT01089608 Phase 2 Azithromycin;Povidone
29 Topical IL-1-Ra for Treatment of Posterior Blepharitis Completed NCT00681109 Phase 1, Phase 2 2.5% IL-1Ra;Placebo;5% IL-1Ra
30 Treatment of Patients With Blepharitis and Facial Rosacea Completed NCT00560703 Phase 2 COL-101 (doxycycline, USP) capsules;placebo
31 The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period Completed NCT00892970 Phase 2 Azithromycin ophthalmic solution, 1%;Placebo
32 The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638) Completed NCT00894530 Phase 2 Azithromycin ophthalmic solution, 1%;Placebo
33 Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease Completed NCT02218489 Phase 2 KPI-121;Vehicle
34 Evaluation and Treatment of Eye Complications of Vaccinia Vaccination Completed NCT00081835 Phase 2 NP-016 Vaccine Immune Globulin (IV-VIG)
35 Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis Recruiting NCT03926026 Phase 2 Fluticasone Propionate;Placebo
36 Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma Active, not recruiting NCT01740297 Phase 1, Phase 2 Talimogene laherparepvec;Ipilimumab
37 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis (P08636) Terminated NCT01269658 Phase 2 Azithromycin ophthalmic solution, 1%;Vehicle
38 A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641) Terminated NCT01220258 Phase 2 Azithromycin ophthalmic solution, 1%
39 A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates Terminated NCT00579020 Phase 2 Moxifloxacin/dexamethasone phosphate ophthalmic solution;Moxifloxacin ophthalmic solution 0.5%;Dexamethasone phosphate solution, 0.1%
40 Study to Determine the Effect of Azasite on Corneal Surface Irregularity Withdrawn NCT01797107 Phase 2 Azasite
41 Demodex Blepharitis Treatment Study Completed NCT01647217 Phase 1 Terpinen-4-ol
42 Efficacy of iLid Cleanser (Avenova) Versus Vehicle on Ocular Skin Flora Unknown status NCT02455895 Not Applicable
43 Ocular Comfort and Inflammation in Lid Hygiene Therapy Unknown status NCT02938078 Not Applicable
44 Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in Glaucoma Unknown status NCT01284439 Not Applicable hydroxypropylmethylcellulose;sodium hyaluronate
45 Study to Evaluate the Safety and Efficacy of HI-BRITE Large Diameter Rigid Gas Permeable Contact Lens Unknown status NCT02812316 Not Applicable
46 Blephacura Versus Baby Shampoo to Treat Blepharitis Completed NCT01115192 Not Applicable
47 To Compare Blephapad Combo vs Standard Treatment for Eyelid Cleansing in Bilateral Posterior Blepharitis Completed NCT03301844 Not Applicable
48 Comparison of BlephEx to MiBoflo as Treatment Options for Blepharitis Completed NCT02952079 Not Applicable
49 Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery Completed NCT01808560 Not Applicable
50 Effects of Systane Versus Saline in Maintaining Tear Film Stability at Determined Time Points Completed NCT00345241 Not Applicable Systane Ocular Drops (OTC);Placebo - Saline Drops

Search NIH Clinical Center for Blepharitis

Cochrane evidence based reviews: blepharitis

Sources

Genetic Tests for Blepharitis

About this section
Sources

Anatomical Context for Blepharitis

About this section

MalaCards organs/tissues related to Blepharitis:

42
Eye, Skin, Testes
Sources

Publications for Blepharitis

About this section

Articles related to Blepharitis:

(show top 50) (show all 308)
# Title Authors Year
1
Prevalence and Load of Demodex folliculorum and Demodex brevis (Acari: Demodicidae) in Patients With Chronic Blepharitis in the Province of Erzincan, Turkey. ( 30137440 )
2019
2
Blepharitis Preferred Practice Pattern®. ( 30366800 )
2019
3
Healthcare delivery in meibomian gland dysfunction and blepharitis. ( 30458245 )
2019
4
MEN 2B masquerading as chronic blepharitis and euryblepharon. ( 30688132 )
2019
5
Long Term Side effects Including Blepharitis Leading to Discontinuation of Ripasudil. ( 30720574 )
2019
6
Blepharitis in dogs: a clinical evaluation in 102 dogs. ( 30828906 )
2019
7
Is it always blepharitis? Urbach-Wiethe syndrome (lipoid proteinosis). ( 30916217 )
2019
8
Efficacy and Safety of Wet Wipes Containing Hy-Ter® Solution Compared with Standard Care for Bilateral Posterior Blepharitis: A Preliminary Randomized Controlled Study. ( 30929188 )
2019
9
The Clinical Use of Eyelash Manipulation in the Diagnosis of Demodex folliculorum Blepharitis. ( 30950926 )
2019
10
Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series. ( 31088416 )
2019
11
The efficacy of tea tree face wash, 1, 2-Octanediol and microblepharoexfoliation in treating Demodex folliculorum blepharitis. ( 29074306 )
2018
12
Randomized double-masked trial of eyelid cleansing treatments for blepharitis. ( 29128682 )
2018
13
Blepharitis as an early sign of metabolic syndrome: a nationwide population-based study. ( 29146760 )
2018
14
The association of keratoconus with blepharitis. ( 29232760 )
2018
15
Development and evaluation of a measure of patient-reported symptoms of Blepharitis. ( 29325546 )
2018
16
Satisfaction and convenience of using terpenoid-impregnated eyelid wipes and teaching method in people without blepharitis. ( 29379270 )
2018
17
Comparison of the Clinical Efficacy of Topical and Systemic Azithromycin Treatment for Posterior Blepharitis. ( 29493395 )
2018
18
The use of tea tree oil in treating blepharitis and meibomian gland dysfunction. ( 29563688 )
2018
19
The impact of age, sex, blepharitis, rosacea and rheumatoid arthritis on Demodex mite infection. ( 29593809 )
2018
20
Better detection of Demodex mites by Löffler's alkaline methylene blue staining in patients with blepharitis. ( 29713140 )
2018
21
Eyelid tinea with blepharitis due to Microsporum canis. ( 29859733 )
2018
22
Blepharitis caused by deep trichophytosis - tinea ciliaris. ( 29927550 )
2018
23
Chronic blepharitis. ( 29947143 )
2018
24
Tiefe Trichophytie unter dem Bild einer Blepharitis - Tinea ciliaris. ( 29989360 )
2018
25
Evaluation of the Efficacy of Tea Tree Oil On the Density of Demodex Mites (Acari: Demodicidae) and Ocular Symptoms In Patients With Demodectic Blepharitis. ( 30016200 )
2018
26
Relationship between blepharitis and components of the metabolic syndrome. ( 30031612 )
2018
27
Investigation of Demodex Parasite Existence in Treatment-Resistant Chronic Blepharitis Cases. ( 30070644 )
2018
28
Quantitative Analysis of the Bacteria in Blepharitis With Demodex Infestation. ( 30108572 )
2018
29
Safety and efficacy of 4-terpineol against microorganisms associated with blepharitis and common ocular diseases. ( 30123842 )
2018
30
Demodex blepharitis: clinical perspectives. ( 30214343 )
2018
31
Phthiriasis palpebrarum presenting as anterior blepharitis. ( 30232978 )
2018
32
Occurrence of Demodex species in patients with blepharitis and in healthy individuals: a 10-year observational study. ( 30255395 )
2018
33
Association of Blepharitis and Ectropion With Tumor Necrosis Factor α Inhibitor Treatment in Crohn Disease. ( 30419086 )
2018
34
Severe chronic blepharitis. Torpid evolution of several years. ( 30447950 )
2018
35
Acute blepharitis: an unusual complication of zoledronic acid. ( 26412501 )
2017
36
RETRACTED: Azithromycin 1.5% Ophthalmic Solution for Blepharitis Treatment: Comparison of 14- Versus 30-Day Treatment. ( 26717146 )
2017
37
The Effect of Demodex Infestation on Blepharitis and the Ocular Symptoms. ( 26783981 )
2017
38
Loteprednol Etabonate 0.5%/Tobramycin 0.3% Compared with Dexamethasone 0.1%/Tobramycin 0.3% for the Treatment of Blepharitis. ( 26788833 )
2017
39
Ten-year incidence and prevalence of clinically diagnosed blepharitis in South Korea: a nationwide population-based cohort study. ( 28183148 )
2017
40
High prevalence of Demodex spp. infestation among patients with posterior blepharitis: correlation with age and cylindrical dandruff. ( 28552438 )
2017
41
Retraction of: Azithromycin 1.5% Ophthalmic Solution for Blepharitis Treatment: Comparison of 14- Versus 30-Day Treatment; DOI: 10.1089/jop.2015.0099. ( 28605219 )
2017
42
Demodex Blepharitis Treated with a Novel Dilute Povidone-Iodine and DMSO System: A Case Report. ( 28643231 )
2017
43
Meibography for eyes with posterior blepharitis. ( 28860908 )
2017
44
Blepharitis With Facial Numbness and Ocular Pain. ( 28880989 )
2017
45
Unilateral Blepharitis With Fine Follicular Scaling. ( 28920471 )
2017
46
Tacrolimus Ointment for Refractory Posterior Blepharitis. ( 28922018 )
2017
47
Preclinical development of MGO Manuka Honey microemulsion for blepharitis management. ( 29354709 )
2017
48
Randomised masked trial of the clinical safety and tolerability of MGO Manuka Honey eye cream for the management of blepharitis. ( 29354710 )
2017
49
Chronic blepharitis like picture in patients with Discoid lupus erythematosis - Case series. ( 29634708 )
2017
50
Meibomian gland dysfunction: azithromycin and objective improvement in outcomes in posterior blepharitis. ( 27314917 )
2016
Sources

Variations for Blepharitis

About this section

ClinVar genetic disease variations for Blepharitis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 STAT1 NM_007315.3(STAT1): c.821G> A (p.Arg274Gln) single nucleotide variant Pathogenic rs387906760 GRCh37 Chromosome 2, 191859910: 191859910
2 STAT1 NM_007315.3(STAT1): c.821G> A (p.Arg274Gln) single nucleotide variant Pathogenic rs387906760 GRCh38 Chromosome 2, 190995184: 190995184
Sources

Expression for Blepharitis

About this section
Search GEO for disease gene expression data for Blepharitis.
Sources

Pathways for Blepharitis

About this section

Pathways related to Blepharitis according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 12.16 IL4 PLA2G6 WIPF1
2
Development IGF-1 receptor signaling 23
Show member pathways
 11.99 CCL11 IL4 STAT1
3
IL-17 Family Signaling Pathways 66
Show member pathways
 11.91 CCL11 IL4 MMP9
4
Bacterial infections in CF airways 23
Show member pathways
 11.76 CCL11 IL4 STAT1
5
Spinal Cord Injury 1
11.51 IL4 MMP9 PLA2G6
6
Interleukin-4 and 13 signaling 67
11.31 CCL11 IL4 MMP9 STAT1
7
Microglia Activation During Neuroinflammation: Microglia Polarization 66
11.18 CCL11 IL4 MMP9
8
FGF signaling pathway 1
11.17 MMP9 STAT1
9
Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway 1
11.15 CCL11 STAT1
10
Th2 Differentiation Pathway 66
11.12 CCL11 IL4
11
Lung fibrosis 1
10.72 CCL11 CMA1 IL4 MMP9
12
Immune response_Oncostatin M signaling via JAK-Stat in human cells 23
10.6 CCL11 STAT1
Sources

GO Terms for Blepharitis

About this section

Biological processes related to Blepharitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of release of cytochrome c from mitochondria GO:0090200 8.96 MMP9 PLA2G6
2 cytokine-mediated signaling pathway GO:0019221 8.92 CCL11 IL4 MMP9 STAT1
Sources

Sources for Blepharitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....